NOVOMIX-30

This brand name is authorized in Australia, Austria, Brazil, Canada, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Lithuania, Netherlands, New Zealand, Nigeria, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug NOVOMIX-30 contains one active pharmaceutical ingredient (API):

1	Insulin aspart UNII 978D8U419H - SACCHAROMYCES CEREVISIAE
	The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulin aspart produces a more rapid onset of action compared to soluble human insulin, together with a lower glucose concentration, as assessed within the first four hours after a meal. Insulin aspart has a shorter duration of action compared to soluble human insulin after subcutaneous injection.
	Read more about Insulin aspart

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10AD05	Insulin aspart	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10A Insulins and analogues → A10AD Insulins and analogues for injection, intermediate-acting combined with fast-acting
Discover more medicines within A10AD05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	12238D, 8609D
BR	Câmara de Regulação do Mercado de Medicamentos	526602001159415, 526602002155316
CA	Health Products and Food Branch	02265435
EE	Ravimiamet	1084788, 1084823, 1214468, 1214479, 1523786
ES	Centro de información online de medicamentos de la AEMPS	00142009, 00142015, 00142021
FI	Lääkealan turvallisuus- ja kehittämiskeskus	001490, 006024
FR	Base de données publique des médicaments	61693569, 64239493, 67832552, 68182431
GB	Medicines & Healthcare Products Regulatory Agency	143813, 143865, 201635, 32773, 32781, 376949, 376952, 379926
HK	Department of Health Drug Office	52604, 61546
IE	Health Products Regulatory Authority	64275, 68927, 68930, 76140
IL	מִשְׂרַד הַבְּרִיאוּת	4621
LT	Valstybinė vaistų kontrolės tarnyba	1004366, 1008620, 1029898, 1029899, 1059246, 1059247, 1059248
NG	Registered Drug Product Database	A6-0204
Switch country to Nigeria in order to find specific presentations of NOVOMIX-30
NL	Z-Index G-Standaard	14719509, 14719517
NL	Z-Index G-Standaard, PRK	121320, 121339, 121347, 65749
NZ	Medicines and Medical Devices Safety Authority	10731, 9745
PL	Rejestru Produktów Leczniczych	100102170, 100108906
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W08254001, W08254002, W08973001, W08973002
SG	Health Sciences Authority	12190P, 15480P
TN	Direction de la Pharmacie et du Médicament	5993082
TR	İlaç ve Tıbbi Cihaz Kurumu	8699676950690, 8699676950706
ZA	Health Products Regulatory Authority	35/21.1/0031